

MAY.12.2003

6:13PM

TTC-PA 650-326-2422

NO.612

P.6/19

PATENT

DALE B. SCHENK *et al.*
Application No.: 09/724,288
Page 2

Amendments to the Specification

Please replace the paragraph on page 7, spanning lines 27-28 with the following six replacement paragraphs.

Figs. 15A-E: A β levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 in combination with different adjuvants. The A β level for individual mice in each treatment group, and the median, mean, and p values for each treatment group are shown.

Fig. 15A: The values for mice in the PBS-treated control group and the untreated control group.

Fig. 15B: The values for mice in the AN1528/alum and AN1528/MPL-treatment groups.

Fig. 15C: The values for mice in the AN1528/QS21 and AN1792/Freund's adjuvant treatment groups.

Fig. 15D: The values for mice in the AN1792/Thimerosal and AN1792/alum treatment groups.

Fig. 15E: The values for mice in the AN1792/MPL and AN1792/QS21 treatment groups.

Please replace the paragraph beginning on page 76, line 17 with the following replacement paragraph:

To prepare formulation doses with alum (Groups 1 and 5). A β peptide in PBS was added to Alhydrogel (two percent aqueous aluminum hydroxide gel, Sargeant, Inc., Clifton, NJ) to reach concentrations of 100 μ g A β peptide per \pm 2 mg of alum. 10X PBS was added to a

MAY.12.2003 6:13PM

TTC-PA 650-326-2422

NO.612

P.7/19

DALE B. SCHENK *et al.*
Application No.: 09/724,288
Page 3

PATENT

D²

final dose volume of 200 ml in 1X PBS. The suspension was then gently mixed for approximately 4 hr at RT prior to injection.